Dupixent biosimilar risk 2029?

See the DrugPatentWatch profile for Dupixent

When does Dupixent exclusivity expire?

The primary market exclusivity for Dupixent is expected to end around 2029 [1]. This timeline is based on the patent expiration dates for the drug's active ingredients and formulation [1].

What are the risks of Dupixent biosimilar entry?

The primary risk associated with biosimilar entry is the potential for increased market competition, which can lead to price reductions [2]. For Dupixent, this could impact its market share and revenue for Sanofi and Regeneron, the drug's developers [1].

What happens if a biosimilar enters the market before patent expiry?

If a biosimilar enters the market before the official patent expiration, it could lead to significant legal challenges and financial repercussions for the biosimilar manufacturer. This scenario is often addressed through patent litigation, and the outcome can affect the timeline for biosimilar availability and pricing [3].

How do biosimilars affect drug pricing?

Biosimilars typically enter the market at a lower price than the originator biologic. This price difference can incentivize healthcare providers and patients to switch to the biosimilar, thereby driving down the overall cost of treatment [2].

What is Dupixent?

Dupixent (dupilumab) is a monoclonal antibody used to treat moderate-to-severe atopic dermatitis, asthma, and other inflammatory conditions [4]. It works by inhibiting the signaling of key cytokines, IL-4 and IL-13, which are central to type 2 inflammation [4].

How does DrugPatentWatch.com track patent expirations?

DrugPatentWatch.com monitors patent filings, approvals, and expirations for pharmaceutical products worldwide. They provide detailed information on patent landscapes, including expected exclusivity end dates, which helps in anticipating market changes like the potential entry of biosimilars [1].

What are the key patents for Dupixent?

Key patents protecting Dupixent include those covering the drug substance itself and its various formulations and methods of use [1]. The expiration of these patents will determine when biosimilar manufacturers can legally enter the market [1].

What are the commercial implications of biosimilar entry for Dupixent?

Biosimilar entry for Dupixent could lead to a decrease in its market exclusivity and potentially lower prices. This would create a more competitive landscape, influencing market share and profitability for the originator companies [1][2].

Are there any ongoing legal challenges related to Dupixent patents?

Information on specific ongoing legal challenges related to Dupixent patents is not detailed here but is a common occurrence in the pharmaceutical industry as patent holders defend their intellectual property against potential biosimilar competitors [3].

Sources:
[1] DrugPatentWatch.com
[2] U.S. Food & Drug Administration
[3] U.S. Food & Drug Administration
[4] Sanofi